Insider Transactions in Q4 2022 at Biodesix Inc (BDSX)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 21
2022
|
Jon Faiz Kayyem |
BUY
Exercise of conversion of derivative security
|
Direct |
31,619
+50.0%
|
-
|
|
Dec 16
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
10,000
+0.05%
|
$10,000
$1.7 P/Share
|
|
Dec 15
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.1%
|
$20,000
$1.65 P/Share
|
|
Dec 14
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
189,675
+0.93%
|
$189,675
$1.65 P/Share
|
|
Dec 13
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
67,402
+0.33%
|
$67,402
$1.58 P/Share
|
|
Dec 12
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.5%
|
$100,000
$1.48 P/Share
|
|
Nov 21
2022
|
Lawrence T. Kennedy Jr |
BUY
Open market or private purchase
|
Indirect |
10,869,565
+42.45%
|
$10,869,565
$1.15 P/Share
|
|
Nov 21
2022
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
17,391
+15.91%
|
$17,391
$1.15 P/Share
|
|
Nov 21
2022
|
Robert William Georgantas Iii Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+23.95%
|
$12,000
$1.15 P/Share
|
|
Nov 21
2022
|
Jon Faiz Kayyem |
BUY
Open market or private purchase
|
Indirect |
173,913
+50.0%
|
$173,913
$1.15 P/Share
|
|
Nov 21
2022
|
Matthew Strobeck |
BUY
Open market or private purchase
|
Indirect |
1,799,997
+47.16%
|
$1,799,997
$1.15 P/Share
|
|
Nov 21
2022
|
Matthew Strobeck |
BUY
Open market or private purchase
|
Direct |
869,565
+26.47%
|
$869,565
$1.15 P/Share
|
|
Nov 21
2022
|
Kieran O'Kane Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,347
+18.21%
|
$4,347
$1.15 P/Share
|
|
Nov 21
2022
|
Scott Hutton President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
65,217
+27.58%
|
$65,217
$1.15 P/Share
|
|
Nov 21
2022
|
Ryan H Siurek Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,695
+26.85%
|
$8,695
$1.15 P/Share
|
|
Nov 21
2022
|
Jack W Schuler |
BUY
Open market or private purchase
|
Indirect |
8,695,652
+30.35%
|
$8,695,652
$1.15 P/Share
|
|
Nov 21
2022
|
John Patience |
BUY
Open market or private purchase
|
Indirect |
1,739,130
+27.65%
|
$1,739,130
$1.15 P/Share
|
|
Nov 21
2022
|
Charles M Watts |
BUY
Open market or private purchase
|
Direct |
43,478
+45.86%
|
$43,478
$1.15 P/Share
|
|
Nov 21
2022
|
Hany Massarany |
BUY
Open market or private purchase
|
Direct |
130,434
+48.6%
|
$130,434
$1.15 P/Share
|
|
Nov 10
2022
|
Ryan H Siurek Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
762
-4.83%
|
$762
$1.02 P/Share
|
|
Nov 10
2022
|
Gary Anthony Pestano Chief Development Officer |
SELL
Open market or private sale
|
Direct |
698
-0.75%
|
$698
$1.02 P/Share
|
|
Nov 10
2022
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
SELL
Open market or private sale
|
Direct |
1,583
-2.08%
|
$1,583
$1.02 P/Share
|
|
Nov 10
2022
|
Scott Hutton President & CEO |
SELL
Open market or private sale
|
Direct |
6,087
-5.43%
|
$6,087
$1.02 P/Share
|
|
Nov 10
2022
|
Robert William Georgantas Iii Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
785
-2.92%
|
$785
$1.02 P/Share
|
|
Nov 10
2022
|
Kieran O'Kane Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
753
-4.72%
|
$753
$1.02 P/Share
|
|
Nov 09
2022
|
Ryan H Siurek Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
963
-5.76%
|
$963
$1.04 P/Share
|
|
Nov 09
2022
|
Gary Anthony Pestano Chief Development Officer |
SELL
Open market or private sale
|
Direct |
882
-0.94%
|
$882
$1.04 P/Share
|
|
Nov 09
2022
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
SELL
Open market or private sale
|
Direct |
1,999
-2.56%
|
$1,999
$1.04 P/Share
|
|
Nov 09
2022
|
Scott Hutton President & CEO |
SELL
Open market or private sale
|
Direct |
7,690
-6.42%
|
$7,690
$1.04 P/Share
|
|
Nov 09
2022
|
Robert William Georgantas Iii Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
991
-3.55%
|
$991
$1.04 P/Share
|
|
Nov 09
2022
|
Kieran O'Kane Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
952
-5.64%
|
$952
$1.04 P/Share
|
|
Nov 08
2022
|
Ryan H Siurek Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,482
+24.69%
|
-
|
|
Nov 08
2022
|
Gary Anthony Pestano Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,054
+5.09%
|
-
|
|
Nov 08
2022
|
Robin Harper Cowie CFO, Sec'y & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,574
+12.91%
|
-
|
|
Nov 08
2022
|
Scott Hutton President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,778
+27.21%
|
-
|
|
Nov 08
2022
|
Robert William Georgantas Iii Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,646
+16.84%
|
-
|
|
Nov 08
2022
|
Kieran O'Kane Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,461
+24.43%
|
-
|